TICAM1, Cell Signaling Technology, 16809

Our team has carried out deep research in the published scientific literature to identify papers and reports using antibodies directed against human TIR domain–containing adapter molecule 1 and followed up by extraction and evaluation of the available data to assess its performance according to pAbmAbs rating criteria.

YCharOS is here conducting a large head-to-head study comparing 6 commercial research antibodies against human TIR domain–containing adapter molecule 1 encoded by TICAM1.

The antibody panel was evaluated in U-87 MG WT and TICAM1 KO cells across multiple applications, including Western blotting (WB; WT and KO lysates, 30 µg protein), immunoprecipitation (IP; WT lysates), and immunofluorescence (IF; WT and KO cells), following YCharOS standard protocols (see reference). In addition, the antibody was tested in a broader panel of cell lines, including U-87 MG WT and TICAM1 KO, BT-549, HCT 116, Bx-PC3, HT-1080, AsPC-1, 5637, A-172, and OCUM-1.

In WB (1:500 ab dilution) 16809 detected a band of appr. 100 kDa in WT cell lysate with no corresponding band observed in KO cell lysate. 16809 also detected a band of appr. 100 kDa across the different cell lines in WB. A band was detected following IP (2 µg Ab used), this band was more intense compared to band in input extract (6% of starting material) and no band was detected in immunodepleted extract (6% of total unbound fraction), showing that the antibody does completely deplete the antigen from cell lysate. In IF (1:100 ab dilution) a more intense staining was observed in WT cells compared to KO cells showing some background.

We highly encourage other scientists to share their observations.